Amgen Inc. is facing significant downward pressure in the market as competition intensifies in the biotech sector.
Amgen Inc. (NASDAQ:AMGN) saw its stock price drop by 2.76%, closing at CA$409.88. This decline comes as competition heats up in the weight-loss drug market, especially from major players like Eli Lilly and Novo Nordisk, who are making headlines with their latest drug advancements.
Investor takeaway: Investors should be cautious as Amgen navigates a challenging competitive landscape, particularly in the lucrative GLP-1 market, where it risks losing market share to more aggressive players.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$229.03B
P/E
26.0x
Div. yield
2.34%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+3.80%
Beta
0.43
Analyst Price Targets
Based on 32 analysts covering AMGN · as of Sep 30, 2026
Wall Street analysts forecast AMGN stock price to rise 1155.0% over the next 12 months.
Consensus
Buy3.63 / 5.00
Avg. Target
C$390.94
+1155.0% Upside
Previously C$389.22 on Sep 25, 2026
Current Price
C$31.15
Last close
Analyst Breakdown (32 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.7%
Annualized
90-Day Vol
32.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$503.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$447.36 | C$388.80 – C$514.74 |
| 60 trading days | C$474.80 | C$389.35 – C$579.00 |
| 90 trading days | C$503.92 | C$395.21 – C$642.53 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Amgen's stock down 2.76% amid competitive pressures
With a market cap of about CA$227.88 billion, Amgen's stock decline reflects investor concerns over its competitive positioning in the biotech sector.
Bull case
Amgen's innovative pipeline, including its long-acting weight-loss injectable MariTide, has potential for future growth if it can stand out in a crowded market.
Bear case
The growing competition from companies like Eli Lilly and Novo Nordisk, which are quickly advancing their own weight-loss drug offerings, could threaten Amgen's market position and profitability.
Advertisement
Intensifying Competition in the Weight-Loss Market
Recent developments at the European Association for the Study of Diabetes (EASD) meeting have highlighted the fierce competition in the weight-loss drug sector. Eli Lilly's new drug, retatrutide, has shown promising results, with 34.9% of patients achieving significant weight loss. Meanwhile, Novo Nordisk reported that its drug, Ozempic, has a lower risk of cardiovascular events compared to Lilly's offerings. This competitive landscape poses a significant challenge for Amgen, which is striving to carve out its niche with MariTide.
Market Reactions and Future Outlook
As Amgen's stock continues to slide, investors are increasingly wary of its ability to compete effectively against established players. With a P/E ratio of 26.31, the company needs to show strong growth and innovation to regain investor confidence. Analysts suggest that while Amgen's pipeline remains promising, the immediate pressure from competitors could hinder its stock performance in the near term.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
